<DOC>
	<DOCNO>NCT00781872</DOCNO>
	<brief_summary>Multiple sclerosis multifocal inflammatory disease central nervous system affect young individual cause paralysis limb , sensation , visual sphincter problem . The disease cause autoimmune mechanism , ie immune system produce antibody cell attack self myelin antigen , cause therefore demyelination . The disease clinically evident relapse neurological disability due dysfunction area ( plaque multiple sclerosis ) damage myelin occur . Disability accumulate time disease enters progressive phase due damage axon irreversible neurodegeneration . Although , effective immunotherapy exist downregulate autoimmune anti-myelin reactivity reduce rate relapse MS ( like Copaxone interferon ) , effective mean today stop progression disability induce rebuild destroy myelin ( re-myelination ) . Neuronal stem cell show possess ability restore neuronal activity produce new neuron transdifferentiation . Various type stem cell test animal model promise result , reveal potential restoration neurological function neuroimmune neurodegenerative condition central nervous system traumatic injury . Adult bone marrow derive stromal cell ( MSC ) show induce similar ( neuronal stem cell ) immunomodulatory neuroregenerative effect show laboratory induce neuroprotection animal model chronic experimental autoimmune encephalomyelitis ( EAE ) . These bone marrow derive MSCs offer practical advantage clinical therapeutic application , since obtain adult bone marrow therefore patient donor , without danger rejection cell . In addition , MSCs carry safer profile less prone malignant transformation . Our initial clinical experience 10 patient ALS 10 multiple sclerosis show intravenous intrathecal administration MSCs feasible safe . In study propose explorative protocol injection MSCs ( intrathecally intravenously ) patient MS , effort prevent neurodegeneration neuroprotective mechanism induce neuroregeneration restoration neuronal function . This phase I/II study . The primary endpoint evaluate safety feasibility treatment MSC infusion , MS patient . Additionally , migration ability transplant cell evaluate tag MSCs superparamagnetic iron oxide particle ( Feridex ) ( FDA approve cell track drug ) detection MRI . MRI brain spinal cord perform week 1 , 4 , 12 24 detect migration stem cell . Clinically patient follow monthly evaluation MS functional rating scale ( EDSS ) scale . The MRI , also use evaluate change total volume lesion brain degree atrophy . Significance : Our center perform first clinical trial intrathecal intravenous injection adult stem cell MS ALS patient gain experience last 3 year type stem cell treatment . After evaluated safety feasibility issue , intent proceed second stage , evaluate migration ability cell ( ability reach affect motor area CNS gray matter , track paramagnetic material visualize MRI ) , evaluate indication clinical efficacy . This project may provide information possible therapeutic us type bone marrow adult stem cell MS ALS may also serve pilot platform pave path future application various type stem cell neurodegerative disease general .</brief_summary>
	<brief_title>Mesenchymal Stem Cells Treatment MS</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>1 . Consenting patient fulfil Poser 's clinical criterion definite MS 2 . Age : 3565 , male females 3 . Duration disease : &gt; 5 year 4 . Failure currently available register MS immunomodulatory treatment ( ie interferon , Copaxone , immunosuppression ) : lack response ( least two ) treatment determined/defined either increase ( deterioration ) least one degree EDSS score last year appearance least two major relapse MS period time ( treatment ) . Exclusion criteria 1 . Patients treat cytotoxic medication ( cyclophosphamide , Mitoxanthrobne etc ) last 3 month prior inclusion 2 . Patients suffer significant cardiac , renal hepatic failure disease may risk patient interfere ability interpret result 3 . Patients active infection 4 . Patients severe cognitive decline inability understand sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>multiple sclerosis ( MS )</keyword>
	<keyword>bone marrow stromal cell</keyword>
	<keyword>stem cell</keyword>
</DOC>